The aim of this analysis was to characterize a large, real-world cohort of HER2-positive patients with BMs, to compare their clinical characteristics with those of other tumor subtypes, as well as to evaluate the survival rates and factors associated with survival in HER2-positive patients with BMs. The gene discussed is ERBB2; the disease is neoplasm.